Novartis | NOVN - Eigenkapital Und Reserven





Eigenkapital Und Reserven Veränderung Datum
AbbVie USD -5.94B 721M 2026-06
Alcon AG USD 21.6B 538M 2026-06
Almirall EUR 1.53B 43.26M 2026-06
Amgen USD 11.69B 2.5B 2026-06
AstraZeneca USD 50.3B 2.96B 2026-06
Autolus Therapeutics Ltd USD 74.84M 33.99M 2026-06
Bayer EUR 29.71B 863M 2026-06
Biogen USD 18.85B 196.3M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Eli Lilly USD 33.88B 2.68B 2026-06
Fresenius EUR 19.7B 766M 2026-06
Fresenius Medical Care EUR 13.53B 673.44M 2026-06
Genmab DKK 5.96B 275M 2026-06
Gilead Sciences USD 11.74B 11.77B 2026-06
GlaxoSmithKline GBP 17.64B 223M 2026-06
GRIFOLS EUR 7.98B 2.52B 2026-06
Hikma Pharmaceutical USD 2.59B 42M 2025-12
J&J USD 84.97B 3.78B 2026-06
Lakefront Biotherapeutics EUR 3.26B 10.26M 2026-06
Lonza CHF 9.13B 513M 2025-12
Merck EUR 30.17B 430M 2026-06
Merck USD 41.93B 3.94B 2026-06
Novartis USD 41.95B 3.02B 2026-06
Novartis USD 38.93B 7.2B 2026-03
Novo Nordisk DKK 221.28B 18.21B 2026-06
Orion EUR 1.27B 146.5M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Philips EUR 11.48B 84M 2026-06
Recordati EUR 2.13B 70.34M 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 32.69B 1.11B 2026-06
Sanofi EUR 69.57B 3.24B 2026-06
UCB EUR 10.87B 1.18B 2025-12